Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The Food and Drug Administration (FDA) in partnership with OSI Pharmaceuticals Inc., and Genentech have issued a warning letter to healthcare professionals informing them of new safety information added to the WARNINGS AND PRECAUTIONS section of the cancer treatment drug Tarceva.

The new information, gathered from a clinical study and postmarketing reports, revealed sometimes fatal incidences of gastrointestinal perforation, bullous, blistering and exfoliative skin conditions including cases suggestive of Stevens Johnson Syndrome (SJS) and/or toxic epidermal necrolysis (TEN) and ocular disorders including corneal perforation or ulceration.

Read the rest of this entry »